YOSEMITE: A 3 arm double-blind randomized phase 2 study of gemcitabine, paclitaxel protein-bound particles for injectable suspension, and placebo (GAP) versus gemcitabine, paclitaxel protein-bound particles for injectable suspension and either 1 or 2 truncated courses of demcizumab (GAD)

Annals of Oncology ◽

10.1093/annonc/mdx369.004 ◽

2017 ◽

Vol 28 ◽

pp. v211 ◽

Author(s):

A. Cubillo Gracian ◽

A. Dean ◽

A. Muñoz ◽

M. Hidalgo ◽

R. Pazo-Cid ◽

...

Keyword(s):

Phase 2 ◽

Double Blind ◽

Phase 2 Study ◽

Randomized Phase 2

Download Full-text

Double-blind, placebo-controlled, randomized, phase 2 study to evaluate the efficacy and safety of maintenance therapy with anti-TA-MUC1 monoclonal antibody PankoMab after chemotherapy in patients with recurrent epithelial ovarian carcinoma.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.tps5622 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS5622-TPS5622

Author(s):

Jonathan A. Ledermann ◽

Ingo von Broen ◽

Frank Zimmermann ◽

Johannes Nippgen ◽

Steffen Goletz

Keyword(s):

Monoclonal Antibody ◽

Maintenance Therapy ◽

Ovarian Carcinoma ◽

Epithelial Ovarian Carcinoma ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study ◽

Randomized Phase 2

Download Full-text

A double-blind, placebo-controlled, randomized, phase 2 study to evaluate the efficacy and safety of switch maintenance therapy with the anti-TA-MUC1 antibody PankoMab-GEX after chemotherapy in patients with recurrent epithelial ovarian carcinoma

Annals of Oncology ◽

10.1093/annonc/mdx440.035 ◽

2017 ◽

Vol 28 ◽

pp. v626 ◽

Author(s):

J. Ledermann ◽

J. Sehouli ◽

B. Zurawski ◽

F. Raspagliesi ◽

U. De Giorgi ◽

...

Keyword(s):

Maintenance Therapy ◽

Ovarian Carcinoma ◽

Epithelial Ovarian Carcinoma ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study ◽

Switch Maintenance Therapy ◽

Randomized Phase 2

Download Full-text

Double-Blind, Placebo-Controlled, Randomized Phase 2 Study of the Proapoptotic Agent AT-101 Plus Docetaxel, in Second-Line Non-small Cell Lung Cancer

Journal of Thoracic Oncology ◽

10.1097/jto.0b013e31820a0ea6 ◽

2011 ◽

Vol 6 (4) ◽

pp. 781-785 ◽

Author(s):

Neal Ready ◽

Nina A. Karaseva ◽

Sergey V. Orlov ◽

Alexander V. Luft ◽

Olexandr Popovych ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Second Line ◽

Phase 2 ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study ◽

Randomized Phase 2

Download Full-text

Abstract A084: DENALI: a 3-arm double-blind randomized phase 2 study of carboplatin, pemetrexed, and placebo (CPP) versus carboplatin, pemetrexed, and either 1 or 2 truncated courses of demcizumab (CPD) in patients with non-squamous non-small cell lung cancer (NSCLC)

10.1158/1535-7163.targ-17-a084 ◽

2018 ◽

Author(s):

Brett Hughes ◽

Andrew Dean ◽

Ben Markman ◽

Luke Dreisbach ◽

Mariano Provencio ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Phase 2 ◽

Small Cell Lung ◽

Double Blind ◽

Phase 2 Study ◽

Randomized Phase 2

Download Full-text

Faculty Opinions recommendation of P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725255169.793503497 ◽

2015 ◽

Author(s):

Brendan J Canning

Keyword(s):

Receptor Antagonist ◽

Chronic Cough ◽

Phase 2 ◽

P2x3 Receptor ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

Faculty Opinions recommendation of Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725373625.793505997 ◽

2015 ◽

Author(s):

Adlette Inati ◽

Hussein Abbas

Keyword(s):

Phase 2 ◽

Phase 2 Study ◽

Randomized Phase 2

Download Full-text

Faculty Opinions recommendation of A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725819857.793510074 ◽

2015 ◽

Author(s):

Marilyn Telen

Keyword(s):

Sickle Cell Disease ◽

Sickle Cell ◽

Adult Patients ◽

Phase 2 ◽

Cell Disease ◽

Double Blind ◽

Multicenter Phase ◽

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.734506216.793579336 ◽

2020 ◽

Author(s):

Nathalie Gaspar

Keyword(s):

Adult Patients ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Metastatic Osteosarcoma ◽

Download Full-text

ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer’s disease

Nature Aging ◽

10.1038/s43587-021-00070-2 ◽

2021 ◽

Vol 1 (6) ◽

pp. 521-534

Author(s):

Petr Novak ◽

Branislav Kovacech ◽

Stanislav Katina ◽

Reinhold Schmidt ◽

Philip Scheltens ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Active Immunotherapy ◽

Phase 2 ◽

Phase 2 Study ◽

Randomized Phase 2

Download Full-text

Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial

Oral Oncology ◽

10.1016/j.oraloncology.2021.105192 ◽

2021 ◽

Vol 115 ◽

pp. 105192

Author(s):

Douglas R. Adkins ◽

Jin-Ching Lin ◽

Assuntina Sacco ◽

Jessica Ley ◽

Peter Oppelt ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Human Papillomavirus ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Neck Squamous Cell Carcinoma ◽

Phase 2 ◽

Double Blind ◽

Phase 2 Trial ◽

Randomized Phase 2

Download Full-text